Just a decade ago, during the financial crisis, the life sciences sector, dominated by small-molecule pharmaceuticals, was being squeezed.
Paul England discusses IP and pharma changes of the past decade, for Intellectual Property Magazine
On the one hand, pharma was finding it harder to identify small-molecule targets and match them with candidate drugs. On the other, it was meeting the challenge of generic competition to the ‘blockbuster’ drugs that had driven the market in the previous decade.
Paul England of Taylor Wessing outlines the recent changes in the life sciences sector, including the advance of technology and the implication for patents, for Intellectual Property Magazine.
Taylor Wessing is a full-service international law firm, working with clients in the world’s most dynamic industries. We take a single-minded approach to advising our clients, helping them succeed by thinking innovatively about their business issues. We support clients wherever they want to do business. The firm has a sector focus with experts in technology, media and communications, life sciences and private